tiprankstipranks
Palvella Therapeutics expects cash to fund operations into H2 of 2027
PremiumThe FlyPalvella Therapeutics expects cash to fund operations into H2 of 2027
5d ago
Promising Potential of QTORIN in Addressing Unmet Needs in Vascular Anomalies: A Buy Recommendation for Palvella Therapeutics
Premium
Ratings
Promising Potential of QTORIN in Addressing Unmet Needs in Vascular Anomalies: A Buy Recommendation for Palvella Therapeutics
20d ago
Palvella Therapeutics granted U.S patent for QTORIN Rapamycin
Premium
The Fly
Palvella Therapeutics granted U.S patent for QTORIN Rapamycin
28d ago
High-Impact Catalyst: Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Gel and Favorable Regulatory Environment
PremiumRatingsHigh-Impact Catalyst: Buy Rating for Palvella Therapeutics Driven by Promising QTORIN Gel and Favorable Regulatory Environment
2M ago
Palvella Therapeutics price target raised to $70 from $30 at Cantor Fitzgerald
Premium
The Fly
Palvella Therapeutics price target raised to $70 from $30 at Cantor Fitzgerald
2M ago
Palvella Therapeutics Reports 2024 Financial Results and Updates
Premium
Company Announcements
Palvella Therapeutics Reports 2024 Financial Results and Updates
2M ago
Positive Outlook on Palvella Therapeutics: Buy Rating Backed by Promising QTORIN Rapamycin Potential
PremiumRatingsPositive Outlook on Palvella Therapeutics: Buy Rating Backed by Promising QTORIN Rapamycin Potential
2M ago
Palvella Therapeutics initiated with an Outperform at Scotiabank
Premium
The Fly
Palvella Therapeutics initiated with an Outperform at Scotiabank
2M ago
Palvella Therapeutics Enhances Investor Relations with New Presentation
Premium
Company Announcements
Palvella Therapeutics Enhances Investor Relations with New Presentation
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100